These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17199446)

  • 1. Paradoxical reaction on treatment with 131I.
    Simsek S; Lips P; Comans E; Netelenbos C
    Thyroid; 2006 Dec; 16(12):1321-2. PubMed ID: 17199446
    [No Abstract]   [Full Text] [Related]  

  • 2. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
    Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
    Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Graves' hyperthyroidism after radioiodine treatment for a toxic nodule: is the hyperthyroidism always triggered by 1311 therapy?
    Niepomniszcze H; Pitoia F; Goodall C; Manavela M; Bruno OD
    Thyroid; 2001 Oct; 11(10):991. PubMed ID: 11716050
    [No Abstract]   [Full Text] [Related]  

  • 4. Appearance of Graves'-like disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre.
    Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):129-30. PubMed ID: 7641405
    [No Abstract]   [Full Text] [Related]  

  • 5. [Development of Basedow disease after radioiodine therapy for nodular goiter].
    Cseke B; Balázs C
    Orv Hetil; 2003 Nov; 144(47):2327-9. PubMed ID: 14725052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
    Nygaard B; Jarløv AE; Kristensen LO; Faber J
    Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
    Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of a custom-made lead collar on dose rates of patients treated with 131I.
    Stapel AG; van der Zant FM; Gommans GM; Boer RO; Reigman HI
    Health Phys; 2009 May; 96(5 Suppl 2):S64-8. PubMed ID: 19359844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
    Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter.
    Meller J; Siefker U; Hamann A; Hüfner M
    Exp Clin Endocrinol Diabetes; 2006 May; 114(5):235-9. PubMed ID: 16804797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
    Nygaard B; Knudsen JH; Hegedüs L; Scient AV; Hansen JE
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic radiotherapy of hyperthyroidism].
    Salvatore M; Brunetti A
    Ann Ital Chir; 1989; 60(5):367-71. PubMed ID: 2699388
    [No Abstract]   [Full Text] [Related]  

  • 14. Results of 131I theory for 2,000 thyrotoxic patients: do the effects depend on the dose?
    Zgliczynski S; Gietka-Czernel M; Gorowski T; Bednarski A; Chomicki O; Jastrzebska W; Makowska A; Niegowska E; Pucilowska J; Soszynski P
    Exp Clin Endocrinol; 1991 May; 97(2-3):286-91. PubMed ID: 1915646
    [No Abstract]   [Full Text] [Related]  

  • 15. Graves' disease and thyroid associated ophthalmopathy following radioiodine therapy in euthyroid multinodular goiter.
    Munigoti S; Samat A; Keston Jones M
    Thyroid; 2008 May; 18(5):585. PubMed ID: 18466082
    [No Abstract]   [Full Text] [Related]  

  • 16. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Graves' disease nd toxic nodular goiter--radioiodine therapy].
    Schicha H; Dietlein M
    Nuklearmedizin; 2002 Apr; 41(2):63-70. PubMed ID: 11989300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 131I treatment of nodular non-toxic goitre.
    Nygaard B; Faber J; Hegedüs L; Hansen JM
    Eur J Endocrinol; 1996 Jan; 134(1):15-20. PubMed ID: 8590950
    [No Abstract]   [Full Text] [Related]  

  • 19. Grave's Eye disease developing following radioiodine treatment for toxic nodular goitre.
    Tahrani AA; Rangan S; Moulik P
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):471-3. PubMed ID: 17647147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
    Gedik O; Ozdemir T; Akalin S
    Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.